Developer docs
API playgroundTry for free, no card

Search company profiles

Resolve Therapeutics

Full company profile

uuid002id71

Namestring
Resolve Therapeutics
Websiteurl
resolvebio.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Resolve Therapeutics is a privately-held, pre-revenue clinical-stage biotechnology company founded in 2010 and headquartered in Kirkland, Washington. The company is developing a novel approach to the treatment of Systemic Lupus Erythematosus (SLE) and related autoimmune conditions, including lupus nephritis and Sjögren's syndrome. Resolve operates with a lean team of 1-10 employees and has raised approximately $8.9 million across three disclosed financing tranches in 2011 and 2012, with no subsequent disclosed capital activity. The company's co-founder and CEO is James Posada. As of the available data, the company has no commercial products, no pricing structure, and no revenue-generating operations; its corporate website (resolvebio.com) remained in a "Launching Soon" pre-launch state, indicating no active commercial market presence.

The company's core technological differentiation is its access to the REJOIN-seq platform, developed at the Institut Pasteur de Montevideo. REJOIN-seq can restore and repair partially degraded cell-free RNA (cfRNA) that conventional sequencing methods fail to capture, enabling the identification of disease-related RNA molecules previously considered inaccessible. Resolve is leveraging this capability to identify upstream cfRNA triggers of inflammatory cascades in autoimmune disease. In April 2026, Resolve formalized a collaboration with Institut Pasteur de Montevideo to apply REJOIN-seq toward identifying cfRNA molecules driving inflammation in lupus and Sjögren's syndrome, with the stated aim of accelerating its clinical programs.

Resolve's business model is entirely R&D-oriented with no current commercial revenue mechanics. There are no disclosed pricing models, marketing channels, distribution channels, or customer logos. The company serves an ultimate end market of autoimmune disease patients, particularly those with SLE, lupus nephritis, and Sjögren's syndrome, but does not yet generate revenue from this population. The investor base is concentrated in early-stage life sciences investors Easton Capital, New Science Ventures, and Washington Research Foundation. The data explicitly notes that a similarly named entity, Resolve M Therapeutics (backed by Johnson & Johnson JJDC and General Inception, exited stealth January 2026 with a myeloid MS1 discovery platform), appears to be a distinct company and is not conflated with Resolve Therapeutics in this assessment.

Short descriptiontext

Resolve Therapeutics is a pre-revenue, privately-held clinical-stage biotechnology company developing novel treatments for autoimmune diseases including systemic lupus erythematosus, lupus nephritis, and Sjögren's syndrome, leveraging the REJOIN-seq cell-free RNA platform through a 2026 collaboration with Institut Pasteur de Montevideo.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
autoimmune therapeutics, lupus treatment, rna sequencing, biopharmaceutical development, inflammatory disease research
Industry2 codes
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Autoimmune Disease Therapeutics
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Resolve Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for autoimmune diseases, with a primary focus on Systemic Lupus Erythematosus (SLE), lupus nephritis, and Sjögren's syndrome. The company leverages the REJOIN-seq technology through its collaboration with Institut Pasteur de Montevideo to identify cell-free RNA molecules that drive inflammation, enabling analysis of disease-related molecules previously considered lost by conventional sequencing methods.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Resolve Therapeutics is a biotechnology company focused on autoimmune disease research. The company operates in collaboration with Institut Pasteur de Montevideo using the REJOIN-seq technology to identify cell-free RNA molecules that drive inflammation in diseases such as lupus and Sjögren's. The related entity Resolve M Therapeutics has unveiled a discovery platform leveraging myeloid cell state MS1 to engage pro-resolution immune responses for chronic inflammatory and autoimmune disorders.

Product and service1 record
1Autoimmune Disease Therapeutics Pipeline
CategoryBiopharmaceutical R&D
Description

Pre-clinical and clinical-stage drug development programs targeting Systemic Lupus Erythematosus (SLE), lupus nephritis, and Sjögren's syndrome. The pipeline leverages the REJOIN-seq cfRNA restoration technology to identify upstream inflammatory triggers that drive autoimmune disease pathology.

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Resolve Therapeutics and Institut Pasteur de Montevideo announced a collaboration to use the REJOIN-seq technology to identify cell-free RNA molecules that drive inflammation in autoimmune diseases such as lupus and Sjögren's. The technology, developed at Pasteur, can restore and repair partially degraded cfRNA that conventional sequencing methods cannot capture, enabling analysis of disease-related molecules previously lost. The partnership aims to advance understanding of the upstream triggers of inflammatory cascades in autoimmunity and potentially accelerate Resolve's clinical programs.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Kymera is a clinical-stage biotech developing targeted protein degraders for immunology and inflammation indications. Comparable as a small-cap autoimmune/inflammation biotech with platform-based discovery.

TypeDirect peer
Description

AnaptysBio develops antibody-based therapeutics for autoimmune and inflammatory diseases. Comparable as a clinical-stage immunology biotech with platform technology and indication overlap in autoimmune disease.

3Bristol Myers Squibb
TypeBroad incumbent
Description

BMS markets Benlysta (belimumab), the leading approved therapy for systemic lupus erythematosus. As a major incumbent in SLE, BMS represents the competitive and potential partnering benchmark for any lupus-focused biotech.

4Horizon Therapeutics (Amgen)
TypeBroad incumbent
Description

Horizon (now part of Amgen) built a leading rare and autoimmune disease franchise, including products for Sjögren's-related conditions. Relevant incumbent comparator for autoimmune specialty indications.

TypeDirect peer
Description

Cabaletta Bio is a clinical-stage biotech developing cell therapies for autoimmune diseases including lupus and Sjögren's syndrome. Comparable by indication, stage, and autoimmune therapeutic focus.

TypeDirect peer
Description

Aurinia Pharmaceuticals develops voclosporin (Lupkynis) for lupus nephritis, a directly overlapping indication with Resolve Therapeutics' autoimmune focus. Comparable clinical-stage-to-commercial biotech in lupus, with similar patient population and inflammatory mechanism.

TypeBroad incumbent
Description

Novartis has an extensive immunology pipeline including Cosentyx and active development in lupus and related autoimmune indications. Broad incumbent competitor with active inflammation franchise.

8Resolve M Therapeutics
TypeEmerging player
Description

Recently emerged from stealth (January 2026) with Johnson & Johnson JJDC and General Inception backing, Resolve M operates in adjacent autoimmune/inflammation biology via a myeloid cell state MS1 platform. Comparable as a similarly-named, similarly-staged autoimmune biotech with a distinct but related platform approach.

TypeDirect peer
Description

Annexon is a clinical-stage biotech developing complement-mediated therapies for autoimmune and inflammatory diseases. Comparable as a small-cap, mechanism-focused autoimmune biotech pursuing inflammatory drivers.

TypeBroad incumbent
Description

Lilly has a major immunology portfolio including Olumiant (baricitinib) and is developing next-generation lupus and Sjögren's therapies. Represents a broad incumbent competitor and potential strategic partner for autoimmune assets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Resolve Therapeutics

Autoimmune Disease Therapeuticsresolvebio.com

Resolve Therapeutics is a pre-revenue, privately-held clinical-stage biotechnology company developing novel treatments for autoimmune diseases including systemic lupus erythematosus, lupus nephritis, and Sjögren's syndrome, leveraging the REJOIN-seq cell-free RNA platform through a 2026 collaboration with Institut Pasteur de Montevideo.

What Resolve Therapeutics does

Resolve Therapeutics is a privately-held, pre-revenue clinical-stage biotechnology company founded in 2010 and headquartered in Kirkland, Washington. The company is developing a novel approach to the treatment of Systemic Lupus Erythematosus (SLE) and related autoimmune conditions, including lupus nephritis and Sjögren's syndrome. Resolve operates with a lean team of 1-10 employees and has raised approximately $8.9 million across three disclosed financing tranches in 2011 and 2012, with no subsequent disclosed capital activity. The company's co-founder and CEO is James Posada. As of the available data, the company has no commercial products, no pricing structure, and no revenue-generating operations; its corporate website (resolvebio.com) remained in a "Launching Soon" pre-launch state, indicating no active commercial market presence.

The company's core technological differentiation is its access to the REJOIN-seq platform, developed at the Institut Pasteur de Montevideo. REJOIN-seq can restore and repair partially degraded cell-free RNA (cfRNA) that conventional sequencing methods fail to capture, enabling the identification of disease-related RNA molecules previously considered inaccessible. Resolve is leveraging this capability to identify upstream cfRNA triggers of inflammatory cascades in autoimmune disease. In April 2026, Resolve formalized a collaboration with Institut Pasteur de Montevideo to apply REJOIN-seq toward identifying cfRNA molecules driving inflammation in lupus and Sjögren's syndrome, with the stated aim of accelerating its clinical programs.

Resolve's business model is entirely R&D-oriented with no current commercial revenue mechanics. There are no disclosed pricing models, marketing channels, distribution channels, or customer logos. The company serves an ultimate end market of autoimmune disease patients, particularly those with SLE, lupus nephritis, and Sjögren's syndrome, but does not yet generate revenue from this population. The investor base is concentrated in early-stage life sciences investors Easton Capital, New Science Ventures, and Washington Research Foundation. The data explicitly notes that a similarly named entity, Resolve M Therapeutics (backed by Johnson & Johnson JJDC and General Inception, exited stealth January 2026 with a myeloid MS1 discovery platform), appears to be a distinct company and is not conflated with Resolve Therapeutics in this assessment.

Resolve Therapeutics firmographics

Firmographics
Name
Resolve Therapeutics
Website
https://resolvebio.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
Resolve Therapeutics is a pre-revenue, privately-held clinical-stage biotechnology company developing novel treatments for autoimmune diseases including systemic lupus erythematosus, lupus nephritis, and Sjögren's syndrome, leveraging the REJOIN-seq cell-free RNA platform through a 2026 collaboration with Institut Pasteur de Montevideo.
Ownership category
akta.pro rank

Resolve Therapeutics industry classification

Industry
Product category
Autoimmune Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Autoimmune therapeutics
  • Lupus treatment
  • Rna sequencing
  • Biopharmaceutical development
  • Inflammatory disease research

Where Resolve Therapeutics is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Markets served

Resolve Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Resolve Therapeutics product offering

Product offering

Core offering

Resolve Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for autoimmune diseases, with a primary focus on Systemic Lupus Erythematosus (SLE), lupus nephritis, and Sjögren's syndrome. The company leverages the REJOIN-seq technology through its collaboration with Institut Pasteur de Montevideo to identify cell-free RNA molecules that drive inflammation, enabling analysis of disease-related molecules previously considered lost by conventional sequencing methods.

Product overview

Resolve Therapeutics is a biotechnology company focused on autoimmune disease research. The company operates in collaboration with Institut Pasteur de Montevideo using the REJOIN-seq technology to identify cell-free RNA molecules that drive inflammation in diseases such as lupus and Sjögren's. The related entity Resolve M Therapeutics has unveiled a discovery platform leveraging myeloid cell state MS1 to engage pro-resolution immune responses for chronic inflammatory and autoimmune disorders.

Differentiator

Problem solved

Functional benefit

Products and services

  • Autoimmune Disease Therapeutics Pipeline Pre-clinical and clinical-stage drug development programs targeting Systemic Lupus Erythematosus (SLE), lupus nephritis, and Sjögren's syndrome. The pipeline leverages the REJOIN-seq cfRNA restoration technology to identify upstream inflammatory triggers that drive autoimmune disease pathology.

Companies that use Resolve Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Resolve Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Resolve Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Institut Pasteur de MontevideocoreStrategic or Co-development Partner · 7 April 2026Resolve Therapeutics and Institut Pasteur de Montevideo announced a collaboration to use the REJOIN-seq technology to identify cell-free RNA molecules that drive inflammation in autoimmune diseases such as lupus and Sjögren's. The technology, developed at Pasteur, can restore and repair partially degraded cfRNA that conventional sequencing methods cannot capture, enabling analysis of disease-related molecules previously lost. The partnership aims to advance understanding of the upstream triggers of inflammatory cascades in autoimmunity and potentially accelerate Resolve's clinical programs.

Recent moves4 records

Expansion highlights3 records

Resolve Therapeutics competitors and assessment

Company assessment

Direct peers

  • Kymera Therapeutics: Kymera is a clinical-stage biotech developing targeted protein degraders for immunology and inflammation indications. Comparable as a small-cap autoimmune/inflammation biotech with platform-based discovery.
  • AnaptysBio: AnaptysBio develops antibody-based therapeutics for autoimmune and inflammatory diseases. Comparable as a clinical-stage immunology biotech with platform technology and indication overlap in autoimmune disease.
  • Cabaletta Bio: Cabaletta Bio is a clinical-stage biotech developing cell therapies for autoimmune diseases including lupus and Sjögren's syndrome. Comparable by indication, stage, and autoimmune therapeutic focus.
  • Aurinia Pharmaceuticals: Aurinia Pharmaceuticals develops voclosporin (Lupkynis) for lupus nephritis, a directly overlapping indication with Resolve Therapeutics' autoimmune focus. Comparable clinical-stage-to-commercial biotech in lupus, with similar patient population and inflammatory mechanism.
  • Annexon Biosciences: Annexon is a clinical-stage biotech developing complement-mediated therapies for autoimmune and inflammatory diseases. Comparable as a small-cap, mechanism-focused autoimmune biotech pursuing inflammatory drivers.

Broad incumbents

  • Bristol Myers Squibb: BMS markets Benlysta (belimumab), the leading approved therapy for systemic lupus erythematosus. As a major incumbent in SLE, BMS represents the competitive and potential partnering benchmark for any lupus-focused biotech.
  • Horizon Therapeutics (Amgen): Horizon (now part of Amgen) built a leading rare and autoimmune disease franchise, including products for Sjögren's-related conditions. Relevant incumbent comparator for autoimmune specialty indications.
  • Novartis: Novartis has an extensive immunology pipeline including Cosentyx and active development in lupus and related autoimmune indications. Broad incumbent competitor with active inflammation franchise.
  • Eli Lilly: Lilly has a major immunology portfolio including Olumiant (baricitinib) and is developing next-generation lupus and Sjögren's therapies. Represents a broad incumbent competitor and potential strategic partner for autoimmune assets.

Emerging players

  • Resolve M Therapeutics: Recently emerged from stealth (January 2026) with Johnson & Johnson JJDC and General Inception backing, Resolve M operates in adjacent autoimmune/inflammation biology via a myeloid cell state MS1 platform. Comparable as a similarly-named, similarly-staged autoimmune biotech with a distinct but related platform approach.

Market position

Strengths4 records

Weaknesses1 record

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Resolve Therapeutics social profiles

Digital presence

Resolve Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Resolve Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Resolve Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Resolve Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resolve Therapeutics

What does Resolve Therapeutics do?

Resolve Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for autoimmune diseases, with a primary focus on Systemic Lupus Erythematosus (SLE), lupus nephritis, and Sjögren's syndrome. The company leverages the REJOIN-seq technology through its collaboration with Institut Pasteur de Montevideo to identify cell-free RNA molecules that drive inflammation, enabling analysis of disease-related molecules previously considered lost by conventional sequencing methods.

When was Resolve Therapeutics founded?

Resolve Therapeutics was founded in 2010. It employs 1 to 10 people.

Where is Resolve Therapeutics based?

Resolve Therapeutics is headquartered in Miami, United States, in the North America region.

Who are Resolve Therapeutics's main competitors?

Direct peers on record are Kymera Therapeutics, AnaptysBio, Cabaletta Bio, Aurinia Pharmaceuticals and Annexon Biosciences. Broad incumbents are Bristol Myers Squibb, Horizon Therapeutics (Amgen), Novartis and Eli Lilly. Resolve M Therapeutics is listed as an emerging player.

Does Resolve Therapeutics have an API?

No public API is recorded for Resolve Therapeutics.

What industry is Resolve Therapeutics in?

Resolve Therapeutics's product category is Autoimmune Disease Therapeutics. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireResolve Therapeutics Completes Enrollment in Phase 2 Study of RSLV-132 in Sjögren's DiseaseResolve Therapeutics completed enrollment in its Phase 2 study of RSLV-132 in women with Sjögren's disease, enrolling approximately 110 participants across U.S. sites. The randomized, double-blind, placebo-controlled study evaluates the drug's effect on cardinal symptoms, with topline results expected in the second quarter of 2027.BioSpaceResolve Therapeutics and Institut Pasteur Collaborate to Identify Cell-Free RNA Triggers in AutoimmunityResolve Therapeutics and Institut Pasteur de Montevideo announced a collaboration to use the REJOIN-seq technology to identify cell-free RNA molecules that trigger inflammation in autoimmune diseases such as lupus and Sjögren's. The technology, developed at Pasteur, can restore and repair partially degraded cfRNA that conventional sequencing methods fail to capture, enabling analysis of disease-related molecules previously lost. This partnership aims to advance understanding of the upstream triggers of inflammatory cascades in autoimmune diseases and potentially accelerate Resolve's clinical programs.PR NewswireResolve Therapeutics and Institut Pasteur Collaborate to Identify Cell-Free RNA Triggers in AutoimmunityResolve Therapeutics and Institut Pasteur de Montevideo announced a collaboration to use the REJOIN-seq technology to identify cell-free RNA molecules that drive inflammation in autoimmune diseases such as lupus and Sjögren's. The technology, developed at Pasteur, can restore and repair partially degraded cfRNA that conventional sequencing methods cannot capture. The partnership aims to advance understanding of the upstream triggers of inflammatory cascades in autoimmunity.The Pharma LetterResolve M Therapeutics exits stealth with immune platformResolve M Therapeutics has exited stealth mode, unveiling a discovery platform designed to engage pro-resolution immune responses for chronic inflammatory and autoimmune disorders by harnessing myeloid cell state MS1. The startup was created through a strategic collaboration between Johnson & Johnson’s venture arm, JJDC, and company builder General Inception, drawing on research from Nir Hacohen’s lab at the Broad Institute and Harvard Medical School.PR NewswireResolve Therapeutics to Present at International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS)Resolve Therapeutics, a mid-stage clinical biopharmaceutical company developing non-immunosuppressive drugs for inflammatory diseases, announced that CEO Dr. James Posada will present at the International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS) in Hong Kong on December 4, 2025. The presentation will cover the company's platform technology and clinical progress, including updates on drug candidate RSLV-132, which is undergoing a large confirmatory Phase 2 clinical trial in Sjogren's disease, and preclinical candidate RSLV-145 being developed for subarachnoid hemorrhage and ischemic stroke.PR NewswireResolve Therapeutics Publishes Results of RSLV-132 Phase 2 Long COVID StudyResolve Therapeutics announced the publication of its Phase 2 long COVID clinical trial results for RSLV-132 in the journal Clinical Infectious Diseases, evaluating 108 patients diagnosed with COVID-19 at least six months prior who had continuous severe fatigue. Participants received six doses of RSLV-132 or placebo over two months, with results suggesting patients may benefit from the removal of circulating RNA. The company's CEO noted the data further indicates women may respond better to RSLV-132 and digestion of latent viral RNA compared to men.PR NewswireResolve Therapeutics Announces Publication of Lupus Clinical Trial ResultsResolve Therapeutics announced the publication of results from its Phase 2a clinical trial of RSLV-132 in patients with Systemic Lupus Erythematosus (SLE) in the peer-reviewed journal Lupus Science & Medicine. The proof-of-concept study found that patients with higher disease activity scores (SLEDAI-2k above 9) responded preferentially to treatment that digests extracellular pathogenic RNA compared to those with lower scores. The company's CEO cited mounting evidence supporting extracellular RNA as a drug target in autoimmune diseases.PR NewswireResolve Therapeutics Completes Enrollment of Phase 2 Long Covid Clinical TrialResolve Therapeutics announced the completion of enrollment for its Phase 2 clinical trial of RSLV-132 in long COVID patients experiencing debilitating fatigue, with 113 participants enrolled in the randomized, double-blind, placebo-controlled study (NCT049049621). The last participant will complete the study in January 2023, with top-line data expected to be released in the first quarter of 2023. RSLV-132 is a first-in-class targeted biologic drug designed to remove pro-inflammatory nucleic acids from circulation, and the company is also developing it for lupus and Sjogren's syndrome.PR NewswireResolve Therapeutics Receives FDA Approval to Initiate Phase 2 Clinical Trial of RSLV-132 in Long Covid PatientsResolve Therapeutics received FDA approval to initiate a Phase 2 clinical trial for its drug RSLV-132 in patients with long COVID. The treatment aims to remove circulating pro-inflammatory RNA from patient blood to alleviate symptoms such as severe fatigue and brain fog.PR NewswireRSLV-132 Demonstrates Clinically Meaningful Improvement in Patients With Systemic Lupus Erythematosus in Phase 2a Clinical TrialResolve Therapeutics announced positive Phase 2a clinical trial results for RSLV-132 in 66 patients with Systemic Lupus Erythematosus, showing that 33% of treated patients achieved a 50% reduction in skin disease activity score versus 23% in the placebo group. Patients with more severe systemic disease (higher SLEDAI scores) demonstrated even greater benefit, with 47% achieving SRI-4 response compared to 18% on placebo. The company plans to confirm these findings in a larger Phase 2 study scheduled for 2021.